Investing in Prevention: Pharma's Strategic Shift Toward Proactive Healthcare
The ₹40-crore AI payoff: How Lupin is building a data-first, AI-ready pharma enterprise
Lupin banks on complex generics, speciality products to sustain growth in FY26–27
Towards a Cleaner Future: Bringing Renewable Energy and Green Chemistry into Mainstream Pharma
We are expanding our CDMO capabilities to meet the next wave of complex therapies starting with oncology
Shift in Customer Dynamics Fueling Future-Forward Business Growth
Vice President and Global Head – Corporate Communications
